<DOC>
	<DOC>NCT00913029</DOC>
	<brief_summary>Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.</brief_summary>
	<brief_title>Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)</brief_title>
	<detailed_description>Two hundred patients will be enrolled in the study at up to 21 clinical sites; follow-up is through 1 year.</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Diagnosis of primary openangle glaucoma Male or female at least 18 years of age and able to provide written informed consent Mean IOP (at baseline visit after washout of any medications) must be 22 mm Hg and no greater than 38 mm Hg Likely to be available and willing to attend followup visits Angle closure glaucoma Secondary glaucomas Prior glaucoma procedures Elevated episcleral venous pressure from history of active thyroid orbitopathy, carotidcavernous fistula, orbital tumors, or orbital congestive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>primary open angle glaucoma (POAG)</keyword>
	<keyword>OAG</keyword>
	<keyword>glaucoma</keyword>
</DOC>